尚高生命科学美股招股说明书(2020-12-09版)

424B5 1 form424b5.htm PROSPECTUS SUPPLEMENT(To the Prospectus dated December 19, 2017)Filed Pursuant to Rule 424(b)(5)Registration No. 333-221711 604,900 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, Shineco, Inc. (the “Company”, “we” or “us”) is offering 604,900 shares of our common stock, par value $0.001 per share, directly to selected investors (the “Offering”). We will receive gross proceeds of approximately $1,651,377 from the Offering. The price per share of Common Stock sold in the Offering is $2.73 per share. Shares of our common stock are currently traded on the NASDAQ Capital Market under the symbol “TYHT”. On December 8, 2020, the closing sale price of our common stock was $3.25 per share. As of December 8, 2020, the aggregate market value of our outstanding common stock held by non-affiliates is approximately $8,436,330.5, based on 3,039,943 shares of outstanding common stock, of which 2,595,794 are held by non-affiliates, and a per share price of $3.25 based on the closing sale price of our common stock on December 8, 2020. The aggregate market value of securities sold by or on our behalf pursuant to Instruction I.B.6 of the general instructions to Form S-3 during the period of 12 calendar months immediately prior to and including the date of this prospectus supplement, does not exceed one-third of the aggregate market value of our voting and non-voting common stock held by our non-affiliates, determined as of a date not more than 60 days before the date of sale. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectus supplement and on page 3 of the accompanying prospectus and the risk factors contained in the documents incorporated by reference herein for a discussion of certain risks that should be considered in connection with an investment in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined whether this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Per Share Total Offering price per share of Common Stock $2.73 $1,651,377 Proceeds to us, before estimated expenses, for the Common Stock $2.73 $1,651,377 The date of this prospectus supplement is December 9, 2020. TABLE OF CONTENTS PageProspectus Supplement About This Prospectus Supplementii Cautionary Statement Regarding Forward-Looking Statementsiv Prospectus Supplement SummaryS-1Risk FactorsS-4Use Of ProceedsS-8Description of SecuritiesS-8Plan of DistributionS-8ExpertsS-9Where You Can Find More InformationS-9Incorporation Of Certain Information By ReferenceS-9 Prospectus PROSPECTUS SUMMARY1 RISK FACTORS3 DISCLOSURE REGARDING FORWARD-LOOKING INFORMATION25 USE OF PROCEEDS25DETERMINATION OF OFFERING PRICE25DILUTION25SELLING SECURITY HOLDERS26DESCRIPTION OF SECURITIES TO BE REGISTERED26 i ABOUT THIS PROSPECTUS SUPPLEMENT On November 21, 2017, we filed with the Securities Exchange Commission (the “SEC”) a registration statement on Form S-3 (File No. 333-221711) utilizing a shelf registration process relating to the securities described in this prospectus supplement, which registration statement, as amended, was declared effective on December 19, 2017 (the “Registration Statement”). Under this shelf registration process, we may, from time to time, sell up to $25,000,000 in the aggregate of common stock and other types of securities as specified in the shelf Registration Statement. On January 23, 2018, pursuant to the Registration Statement and an accompanying prospectus supplement dated and filed with the SEC on January 26, 2018 (the “IFG Prospectus Supplement”), we entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with IFG OPPORTUNITY FUND LLC (“IFG Fund”) whereby, upon the terms and subject to the conditions and limitations set forth therein, we have the right, from time to time in our sole discretion during the 24-month term of the Purchase Agreement, to direct IFG Fund to purchase up to a total of $15,000,000 (the “Available Amount”) of shares of common stock. We entered into a Termination Agreement with IFG Fund on July 3, 2018, pursuant to which the Purchase Agreement was terminated, effective immediately. As of the date of this prospectus supplement, no shares under the Available Amount have been issued to IFG Fund by the Company (except for the Commitment Shares). As such, as of the date of this prospectus supplement, except for the 200,000 Commitment Shares,